Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting

J Rheumatol. 2022 Jun;49(6 Suppl 1):57-63. doi: 10.3899/jrheum.211336. Epub 2022 Apr 1.


At the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Collaborative Research Network (CRN) annual meeting, the GRAPPA-CRN group presented a number of project updates, including a pilot investigator-initiated study to evaluate liquid and tissue biomarkers associated with axial involvement in psoriatic arthritis (PsA). The GRAPPA-CRN session updated progress made with 3 parallel international research initiatives based on 3 previously defined unmet needs in PsA. The Health Initiatives in Psoriasis and PsOriatic arthritis ConsoRTium European States (HIPPOCRATES) is a European research consortium formed to address unmet clinical needs in PsA. The Preventing Arthritis in a multicenter Psoriasis At-Risk Population (PAMPA) is a US-based organization that has defined consensus terminology for preclinical phases of PsA and is interested in the transition process from psoriasis to PsA. An overview of the Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) program 2.0, a consortium including GRAPPA-CRN members that addressed these 3 unmet needs in PsA, was also presented.

Keywords: GRAPPA; biomarkers; psoriasis; psoriatic arthritis.

Publication types

  • Multicenter Study

MeSH terms

  • Arthritis, Psoriatic*
  • Humans
  • Organizations
  • Pilot Projects
  • Psoriasis*
  • Rheumatology*